Cover of: Tamoxifen and Breast Cancer (Yale Fastback Series) | Michael W. DeGregorio Read Online
Share

Tamoxifen and Breast Cancer (Yale Fastback Series) by Michael W. DeGregorio

  • 266 Want to read
  • ·
  • 38 Currently reading

Published by Yale University Press .
Written in English

Subjects:

  • Medical research,
  • Oncology,
  • Pharmacology,
  • Breast Cancer,
  • Specific Drugs,
  • Medical / Nursing,
  • Medical,
  • Diseases - Breast Cancer,
  • General,
  • Medical / General,
  • Breast,
  • Cancer,
  • Chemoprevention,
  • Tamoxifen

Book details:

The Physical Object
FormatPaperback
Number of Pages118
ID Numbers
Open LibraryOL9509362M
ISBN 100300079516
ISBN 109780300079517

Download Tamoxifen and Breast Cancer (Yale Fastback Series)

PDF EPUB FB2 MOBI RTF

They present the controversies surrounding the National Cancer Institute's study of tamoxifen as a preventive for breast cancer, describing the hopes of the proponents of the study and the fears of its detractors (potential risks to women in the study include thrombosis, uterine cancer, and even breast cancer itself). The book is an invaluable.   They present the controversies surrounding the National Cancer Institute's study of tamoxifen as a preventive for breast cancer, describing the hopes of the proponents of the study and the fears of its detractors (potential risks to women in the study include thrombosis, uterine cancer, and even breast cancer itself). The book is an invaluable. Tamoxifen is one of the most widely prescribed drugs used to prevent the recurrence of breast cancer. A nonsteroidal antiestrogen, it has been successful in treating postmenopausal women at nearly all stages of breast cancer. Despite its popularity, disturbing questions remain about the use of this drug/5(8).   Distinguished physicians, scientists, breast cancer advocates, and breast cancer survivors have assembled here to answer numerous questions about tamoxifen. Written for both the clinician and patient, this book is a premier source of information about the world's leading drug for the treatment and prevention of breast by:

The first chapter of Tamoxifen: A Guide for Clinicians and Patientsprovides a succinct review of the known risk factors for breast of the remaining 13 chapters, after the thorough historical perspective,specifically address the issue of the use of tamoxifen. Current FDA-approveduses of tamoxifen are provided, as are some relatively. Tamoxifen (Nolvadex) has been used for over 40 years to treat hormone-receptor positive early, locally advanced and metastatic breast cancers. Learn about tamoxifen and other hormone therapies (endocrine therapies) for metastatic breast cancer.. How does tamoxifen work? Hormone receptor-positive breast cancers need estrogen and/or progesterone (female hormones) to grow. Four randomized, masked, placebo-controlled trials of chemoprevention for breast cancer have been reported. Three were trials of tamoxifen in which breast cancer prevention was the primary outcome, and one was a trial of raloxifene in which breast cancer prevention was the secondary outcome. The largest of the three tamoxifen trials, the BCPT, found a strongly favorable effect (49 percent.   This book needs to be updated. The field of treating breast cancer has been changing quickly, and while Tamoxifen idps the same drug, there are other drugs that have all but replaced tamoxifenfor therapy over the initial 5 s: 4.

Tamoxifen is used mainly to treat hormone receptor-positive breast cancer (breast cancer with cells that have estrogen and/or progesterone receptors on them). Raloxifene is used mostly to prevent and treat osteoporosis (very weak bones) in post-menopausal women. To lower the risk of breast cancer, these drugs are taken for 5 years. Tamoxifen and Breast Cancer $ in stock. Tamoxifen and Breast Cancer quantity. Add to cart. SKU: Category. The estrogen receptor (ER) antagonist tamoxifen (trade names include Nolvadex™, Istubal™, Valodex™), is widely used in the treatment of ER-positive breast cancer and breast cancer chemoprevention. Despite the success of tamoxifen in the treatment of ER-positive breast cancer, 30–50% of patients will fail tamoxifen therapy [65, ABSTRACT: Tamoxifen, a nonsteroidal antiestrogen agent, is widely used as adjunctive therapy for women with breast cancer, and it has been approved by the U.S. Food and Drug Administration for adjuvant treatment of breast cancer, treatment of metastatic breast cancer, and reduction in breast cancer incidence in high-risk women. Tamoxifen use may be extended to 10 years based on new .